EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy

Agata Kosmaczewska iD, Lidia Ciszak iD, Anna Andrzejczak iD, Anna Tomkiewicz, Anna Partyka iD, Zofia Rojek-Gajda iD, Irena Frydecka, Dariusz Wołowiec, Tomasz Wróbel, Agnieszka Bojarska-Junak iD, Jacek Roliński iD, Lidia Karabon iD

Biomolecules · 2025

DOI: 10.3390/biom15111499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Agata Kosmaczewska und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Scie…. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Immunologic, T-Lymphocytes. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, Wroclaw Medical University, Medical University of Lublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given that we have demonstrated that miR-155-5p is increased in CLL PBMCs and that its reduction with inhibitory siRNA partially restores the immune checkpoint BTLA protein level in CLL B cells, risk stratification for using anti-miR-155-based immunotherapy in CLL seems reasonable, particularly with its potential impact on T cells. Therefore, we aimed to assess the role of miR-155-5p in the epigenetic modification of BTLA levels in CLL T cells, especially since we observed that BTLA expression unfavorably promotes increased proliferative activity and IL-4 secretion in T cells, thus suggesting BTLA malfunction in the CLL T cell subset. Transfection of PBMCs with an inhibitor of miR-155-5p (INH) led to about a ten-fold down-regulation of miR-155-5p levels compared to control siRNA (NC) both in CLL patients and healthy individuals (HC), as assessed by RT-qPCR. Additionally, we did not find any significant differences in BTLA protein expression in T cells after silencing miR-155-5p in either examined group. We demonstrated for the first time that immunotherapy approaches based on systemic administration of anti-miR-155-5p therapeutics would be a favorable strategy in CLL, since they do not affect BTLA expression in T cell populations and could benefit CLL patients with impaired BTLA levels on CLL cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLeukemia, Lymphocytic, Chronic, B-CellReceptors, ImmunologicT-LymphocytesHumansImmunotherapyFemaleMaleMiddle AgedAgedGene Silencing

Stichwörter der Autor:innen

BTLACLLT cellsepigenetic modificationimmunotherapymiR-155-5p

Substanzen

MicroRNAsBTLA protein, humanMIRN155 microRNA, humanReceptors, Immunologic

Autor:innen und Institutionen

  • Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
  • Laboratory of Genetics and Epigenetics of Human Diseases, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
  • Dental Center STOMO Clinic, 53-411 Wroclaw, Poland.
  • Department and Clinic of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland.

ORCID-Profile: Agata Kosmaczewska, Lidia Ciszak, Anna Andrzejczak, Anna Partyka, Zofia Rojek-Gajda, Agnieszka Bojarska-Junak, Jacek Roliński, Lidia Karabon

Förderung

  • Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
  • Wroclaw Medical University
  • Medical University of Lublin

Zitieren

APA

Kosmaczewska, A., Ciszak, L., Andrzejczak, A., Tomkiewicz, A., Partyka, A., Rojek-Gajda, Z., Frydecka, I., Wołowiec, D., Wróbel, T., Bojarska-Junak, A., Roliński, J., & Karabon, L. (2025). miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy. Biomolecules. https://doi.org/10.3390/biom15111499

Vancouver

Kosmaczewska A, Ciszak L, Andrzejczak A, Tomkiewicz A, Partyka A, Rojek-Gajda Z, et al. miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy. Biomolecules. 2025. doi:10.3390/biom15111499

BibTeX
@article{Kosmaczewska2025,
  author = {Kosmaczewska, Agata and Ciszak, Lidia and Andrzejczak, Anna and Tomkiewicz, Anna and Partyka, Anna and Rojek-Gajda, Zofia and Frydecka, Irena and Wołowiec, Dariusz and Wróbel, Tomasz and Bojarska-Junak, Agnieszka and Roliński, Jacek and Karabon, Lidia},
  title = {miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15111499}
}
Kostenlos starten →